Skip to main content

Advertisement

SpringerLink
Log in

Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Purpose

Metastatic colorectal cancer (mCRC) is a lethal disease and fluorouracil–leucovorin–irinotecan (FOLFIRI) plus bevacizumab (bev) is a standard approach. Hence, there is a strong need for identifying new prognostic factors to show the efficacy of FOLFIRI-bev.

Methods

This is a retrospective study including patients (n = 90) with mCRC from two centers in Turkey. Neutrophil/lymphocyte (N/L) ratio, platelet count, albumin, and C-reactive protein (CRP) were recorded before FOLFIRI-bev therapy. The efficacy of these factors on progression-free survival (PFS) was analyzed with Kaplan Meier and Cox regression analysis. And the cutoff value of N/L ratio was analyzed with ROC analysis.

Results

The median age was 56 years (range 21–80). Forty-seven percent of patients with N/L ratio >2.5 showed progressive disease versus 43 % in patients with N/L ratio <2.5 (p = 0.025). The median PFS was 8.1 months for the patients with N/L ratio >2.5 versus 13.5 months for the patients with N/L ratio <2.5 (p = 0.025). At univariate Cox regression analysis, high baseline neutrophil count, LDH, N/L ratio, and CRP were all significantly associated with poor prognosis. At multivariate Cox regression analysis, CRP was confirmed to be a better independent prognostic factor. CRP variable was divided into above the upper limit of normal (ULN) and normal value. The median PFSs of the patients with normal and above ULN were 11.3 versus 5.8 months, respectively (p = 0.022).

Conclusions

CRP and N/L ratio are potential predictors for advanced mCRC treated with FOLFIRI-bev.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

References

  1. Guthrie GJK, Roxburgh CSD, Horgan PG, McMillan DC. Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer? Cancer Treat Rev. 2013;39:89–96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22858249.

    Article  CAS  PubMed  Google Scholar 

  2. Roxburgh C, McMillan D, Re: Ishizuka, et al. Systemic inflammatory response predicts postoperative outcome in patients with liver metastases from colorectal cancer. J Surg Oncol. 2009;100:616. author reply 617. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19918791.

    Article  PubMed  Google Scholar 

  3. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17287242.

    Article  CAS  PubMed  Google Scholar 

  4. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104:1288–95. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3078587&tool=pmcentrez&rendertype=abstract.

  5. Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg. 1998;176:335–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9817250.

    Article  CAS  PubMed  Google Scholar 

  6. McMillan DC, Wotherspoon HA, Fearon KC, Sturgeon C, Cooke TG, McArdle CS. A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg. 1995;170:319–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7573721.

    Article  CAS  PubMed  Google Scholar 

  7. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291:585–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14762037.

    Article  CAS  PubMed  Google Scholar 

  8. Ko WF, Helzlsouer KJ, Comstock GW. Serum albumin, bilirubin, and uric acid and the anatomic site-specific incidence of colon cancer. J Natl Cancer Inst. 1994;86:1874–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7990163.

    Article  CAS  PubMed  Google Scholar 

  9. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7165009.

    Article  CAS  PubMed  Google Scholar 

  10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19097774.

    Article  CAS  PubMed  Google Scholar 

  11. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Maspero F, et al. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. Clin Colorectal Cancer. 2013;12:145–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23763824.

    Article  CAS  PubMed  Google Scholar 

  12. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91:181–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16118772.

    Article  CAS  PubMed  Google Scholar 

  13. Chung Y-C, Chang Y-F. Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. Eur J Gastroenterol Hepatol. 2003;15:369–73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12655256.

    Article  CAS  PubMed  Google Scholar 

  14. Rifai N, Buring JE, Lee I-M, Manson JE, Ridker PM. Is C-reactive protein specific for vascular disease in women? Ann Intern Med. 2002;136:529–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11926788.

    Article  CAS  PubMed  Google Scholar 

  15. Mallappa S, Sinha A, Gupta S, Chadwick SJD. Preoperative neutrophil to lymphocyte ratio >5 is a prognostic factor for recurrent colorectal cancer. Colorectal Dis. 2013;15:323–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22958479.

    Article  CAS  PubMed  Google Scholar 

  16. Dirican A, Varol U, Kucukzeybek Y, Alacacioglu A, Erten C, Somali I, et al. Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab? Asian Pac J Cancer Prev. 2014;15:4781–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24998541.

    Article  PubMed  Google Scholar 

  17. Formica V, Luccchetti J, Cunningham D, Smyth EC, Ferroni P, Nardecchia A, et al. Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients. Med Oncol. 2014;31:166. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25148896.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Meram Medical Faculty, Necmettin Erbakan University, 42080, Konya, Turkey

    Mehmet Artaç, Mustafa Karaağaç, Levent Korkmaz, Zehra Er, Tunç Güler & Melih Cem Börüban

  2. Department of Medical Oncology, Afyon Kocatepe University Medical Faculty, Afyon, Turkey

    Mükremin Uysal

  3. Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya, Turkey

    Hakan Bozcuk

Authors
  1. Mehmet Artaç
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mükremin Uysal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mustafa Karaağaç
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Levent Korkmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zehra Er
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tunç Güler
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Melih Cem Börüban
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hakan Bozcuk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehmet Artaç.

Ethics declarations

Conflict of Interest Statement

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Artaç, M., Uysal, M., Karaağaç, M. et al. Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab. J Gastrointest Canc 48, 176–180 (2017). https://doi.org/10.1007/s12029-016-9879-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-016-9879-4

Keywords

Search

Navigation